Search Results - "van de Donk, N"

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab by Nijhof, I S, Groen, R W J, Lokhorst, H M, van Kessel, B, Bloem, A C, van Velzen, J, de Jong-Korlaar, R, Yuan, H, Noort, W A, Klein, S K, Martens, A C M, Doshi, P, Sasser, K, Mutis, T, van de Donk, N W C J

“…Daratumumab is an anti-CD38 monoclonal antibody with lytic activity against multiple myeloma (MM) cells, including ADCC (antibody-dependent cellular…”
Get full text

Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab by Laheij, A. M. G. A., van de Donk, N. W. C. J.

“…Purpose In recent years, various immunotherapies have improved the survival of patients with multiple myeloma (MM). However, there remains an unmet need for…”
Get full text

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma by van de Donk, N W C J, Kamps, S, Mutis, T, Lokhorst, H M

“…The introduction of autologous stem cell transplantation combined with the introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors has…”
Get full text

Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis by Slot, S, Smits, K, van de Donk, N W C J, Witte, B I, Raymakers, R, Janssen, J J W M, Broers, A E C, te Boekhorst, P A W, Zweegman, S

“…In myelofibrosis, the introduction of reduced-intensity conditioning (RIC) preceding allogeneic stem cell transplantation (SCT) resulted in lower…”
Get full text

Case report: persistently seronegative neuroborreliosis in an immunocompromised patient by Wagemakers, A, Visser, M C, de Wever, B, Hovius, J W, van de Donk, N W C J, Hendriks, E J, Peferoen, L, Muller, F F, Ang, C W

“…Infection with Borrelia burgdorferi sensu lato complex (B. b. sl) spirochetes can cause Lyme borreliosis, manifesting as localized infection (e.g. erythema…”
Get full text

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma by van de Donk, N. W. C. J., Mutis, T., Poddighe, P. J., Lokhorst, H. M., Zweegman, S.

“…Summary Monoclonal gammopathy of undetermined significance (MGUS) is one of the most common premalignant disorders. IgG and IgA MGUS are precursor conditions…”
Get full text

Treatment sequences and drug costs from diagnosis to death in multiple myeloma by Seefat, M. R., Cucchi, D. G. J., Groen, K., Donker, M. L., Hem, K. G., Westerman, M., Gerrits, A. M., Beeker, A., Donk, N. W. C. J., Blommestein, H. M., Zweegman, S.

“…Novel therapies for multiple myeloma (MM) have improved patient survival, but their high costs strain healthcare budgets. End‐of‐life phases of treatment are…”
Get full text

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma by Franssen, L E, Roeven, M W H, Hobo, W, Doorn, R, Oostvogels, R, Falkenburg, J H F, van de Donk, N W, Kester, M G D, Fredrix, H, Westinga, K, Slaper-Cortenbach, I, Spierings, E, Kersten, M J, Dolstra, H, Mutis, T, Schaap, N, Lokhorst, H M

“…Allogeneic stem cell transplantation (allo-SCT) with or without donor lymphocyte infusions (DLI) is the only curative option for several hematological…”
Get full text

The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs by Franssen, L E, van de Donk, N W C J, Emmelot, M E, Roeven, M W H, Schaap, N, Dolstra, H, Hobo, W, Lokhorst, H M, Mutis, T

“…Allo-SCT followed by DLIs can establish long-term remissions in multiple myeloma (MM) patients. In many patients, however, the immunotherapeutic…”
Get full text

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma by VAN DE DONK, N. W. C. J, KRÖGER, N, AYUK, F. A, VAN OERS, M. H. J, NAGLER, A, VERDONCK, L. F, LOKHORST, H. M, HEGENBART, U, CORRADINI, P, SAN MIGUEL, J. F, GOLDSCHMIDT, H, PEREZ-SIMON, J. A, ZIJIMANS, M, RAYMAKERS, R. A, MONTEFUSCO, V

“…In this retrospective study, we evaluated donor lymphocyte infusions given for relapsed (n=48) or persistent (n=15) myeloma following non-myeloablative…”
Get full text

Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome by Minnema, M C, van de Donk, N W C J, Zweegman, S, Hegenbart, U, Schonland, S, Raymakers, R, Zijlmans, J M J M, Kersten, M J, Bos, G M J, Lokhorst, H M

“…Recent literature suggests that after non-myeloablative allogeneic (NMA) stem cell transplantation (SCT), the incidence of extramedullary (EM) relapse in…”
Get full text

Growth factors and antiapoptotic signaling pathways in multiple myeloma by VAN DE DONK, N. W. C. J, LOKHORST, H. M, BLOEM, A. C

“…Failure of myeloma cells to undergo apoptosis plays an important role in the accumulation of myeloma cells within the bone marrow (BM). Moreover, inhibition of…”
Get full text

Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options by Amaador, K, Peeters, H, Minnema, M C, Nguyen, T Q, Dendooven, A, Vos, J M I, Croockewit, A J, van de Donk, N W C J, Jacobs, J F M, Wetzels, J F M, Sprangers, B, Abrahams, A C

“…Monoclonal gammopathy of renal significance (MGRS) includes all kidney disorders caused by a monoclonal protein (M-protein) secreted by a small plasma cell…”
Get full text

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma by VAN DE DONK, N. W. C. J, DE WEERDT, O, VETH, G, EURELINGS, M, VAN STRALEN, E, FRANKEL, S. R, HAGENBEEK, A, BLOEM, A. C, LOKHORST, H. M

“…Expression of Bcl-2 in multiple myeloma is associated with resistance to chemotherapeutic drugs. Conversely, suppression of Bcl-2 enhanced the chemosensitivity…”
Get full text

Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience by Minnema, M C, van Dorp, S, van de Donk, N W C J, Schouten, F, Kersten, M J, Coenen, J L L M, Schouten, H, Zweegman, S, Schaafsma, R, Lokhorst, H M

“…For relapsed multiple myeloma (MM) patients, allo-SCT is a possible treatment option, but recent data obtained using a nonmyeloablative (NMA) conditioning…”
Get full text

Takotsubo cardiomyopathy following radioiodine therapy for toxic multinodular goitre by VAN DE DONK, N. W. C. J, AMERICA, Y. G. C. J, ZELISSEN, P. M. J, HAMER, B. J. B

“…We report on a 73-year-old man with a toxic multinodular goitre, which was treated with radioiodine therapy (I-131) without pretreatment with an antithyroid…”
Get full text

New developments in the treatment of patients with multiple myeloma by MINNEMA, M. C, VAN DER SPEK, E, VAN DE DONK, N. W. C. J, LOKHORST, H. M

“…Much progress has been made in the treatment of patients with multiple myeloma (MM). The introduction of new drugs such as thalidomide, bortezomib and…”
Get full text

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells by VAN DE DONK, N. W. C. J, KAMPHUIS, M. M. J, LOKHORST, H. M, BLOEM, A. C

“…Lovastatin is an irreversible inhibitor of HMG-CoA reductase and blocks the production of mevalonate, a critical compound in the production of cholesterol and…”
Get full text

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma by Lokhorst, Henk M, Plesner, Torben, Laubach, Jacob P, Nahi, Hareth, Gimsing, Peter, Hansson, Markus, Minnema, Monique C, Lassen, Ulrik, Krejcik, Jakub, Palumbo, Antonio, van de Donk, Niels W.C.J, Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa M, Wang, Jianping, Sasser, A. Kate, Losic, Nedjad, Lisby, Steen, Basse, Linda, Brun, Nikolai, Richardson, Paul G

“…Daratumumab was associated with impressive antitumor responses, including complete and very good partial responses, in heavily pretreated patients with…”
Get full text

Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein by VAN DE DONK, N. W. C. J, KAMPHUIS, M. M. J, VAN DIJK, M, BORST, H. P. E, BLOEM, A. C, LOKHORSTP, H. M

“…An antisense oligodeoxynucleotide (ODN) complementary to the first six codons of the Bcl-2 mRNA, G3139 (oblimersen sodium; Genasense), has been shown to…”
Get full text